https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46794 Wed 30 Nov 2022 14:31:28 AEDT ]]> Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45703 Wed 24 Jan 2024 14:33:03 AEDT ]]> Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48348 Wed 14 Feb 2024 15:59:55 AEDT ]]> The CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in tolerizing dendritic cells https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19680 Sat 24 Mar 2018 07:53:39 AEDT ]]> Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46967 Mon 12 Dec 2022 16:05:23 AEDT ]]> A longitudinal analysis of brain volume changes in myelin oligodendrocyte glycoprotein antibody-associated disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53845 .1). Conclusion: We found evidence of loss of GM and TBV over time in pwMOGAD, similar to pwMS, although the WM and lesion volumes were unchanged.]]> Fri 19 Jan 2024 10:18:15 AEDT ]]>